GSK — GSK plc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1131399 ·
United Kingdom
Last close
$49.24
Market Cap
$98.62B
52W High
$59.57
52W Low
$44.23
ADV30
4,821,901
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 8,887,000,000 | 6,497,000,000 | 2,127,000,000 | 1,543,000,000 | 71,699,000,000 | 2,934,000,000 | 53,337,000,000 |
| Jun 2026 | 8,409,000,000 | 6,143,000,000 | 481,000,000 | 435,000,000 | 61,738,000,000 | 3,105,000,000 | 44,561,000,000 |
| Mar 2026 | 7,629,000,000 | 5,754,000,000 | 2,293,000,000 | 1,737,000,000 | 62,869,000,000 | 3,442,000,000 | 45,447,000,000 |
| Dec 2025 | 8,618,000,000 | 5,961,000,000 | 1,506,000,000 | 636,000,000 | 61,118,000,000 | 3,150,000,000 | 45,162,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$8,918,000,000
Investing CF
$-10,896,000,000
Financing CF
$1,937,000,000
CapEx
$-2,654,000,000
Dividends Paid
$-2,698,000,000
Buybacks
$-886,000,000
EPS Diluted TTM
$2.14
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$12,458,000,000
Inventory
$6,300,000,000
Receivables
—
ST Investments
$28,000,000
EBIT TTM
$6,125,000,000
Pretax Income TTM
$5,383,000,000
Interest Exp TTM
$742,000,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$33,202,999,296
EBITDA
$10,817,999,872
Free Cash Flow
$3,482,625,024
Enterprise Value
$111,147,458,560
Total Cash
$3,105,999,872
Total Debt
$18,293,000,192
Shares Out
2,002,805,623
Trailing EPS
$3.19
Book Value
$11.91
ROE
33.4%
ROA
10.0%
Div Yield
3.78%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 32,667,000,000 | 8,338,000,000 | 5,716,000,000 | 61,118,000,000 | 45,162,000,000 | 16,377,000,000 | 7,741,000,000 |
| Dec 2024 | 31,376,000,000 | 5,542,000,000 | 2,575,000,000 | 59,463,000,000 | 46,377,000,000 | 13,671,000,000 | 6,554,000,000 |
| Dec 2023 | 30,328,000,000 | 7,345,000,000 | 4,928,000,000 | 59,005,000,000 | 46,210,000,000 | 13,347,000,000 | 6,768,000,000 |
| Dec 2022 | 29,324,000,000 | 6,729,000,000 | 14,956,000,000 | 60,146,000,000 | 50,050,000,000 | 10,598,000,000 | 7,403,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$4.98
Max Pain — expiry 2026-12-11 (volume-derived — Yahoo OI feed degraded)
max pain strike: $51.00 · spot: $48.58 · call volume: 414 · put volume: 43Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| REGN | REGENERON PHARMACEUTICALS, INC. | $97.34B | $957.76 | — |
| SNY | Sanofi | $113.89B | $47.53 | — |
| BMY | BRISTOL MYERS SQUIBB CO | $125.40B | $61.35 | — |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $135.44B | $534.20 | — |
| NVO | NOVO NORDISK A S | $136.10B | $40.70 | — |
News headlines (Yahoo Finance, 1h cache)
Former Novartis U.S. Chief Strategy Officer Scott Howell, MD, MBA, Joins GOA Therapeutics as Chief Commercial Officer
2026-11-18 18:30 · Yahoo
GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung Cancer
2026-11-18 15:35 · Yahoo
GSK CFO Points to Cancer Drugs to Bridge £3.4 Billion Sales Forecast Gap
2026-11-18 02:12 · Yahoo
GSK wins FDA approval for lung cancer drug Nelkarmi
2026-11-17 19:18 · Yahoo
GSK Targets £40 Billion in Sales as HIV Patent Cliff Looms
2026-11-17 10:12 · Yahoo
GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments
2026-11-09 19:15 · Yahoo
GSK (LSE:GSK) Stock Still Looks Below Fair Value Following Jemperli Approval
2026-11-06 10:18 · Yahoo
What Does GSK (LSE:GSK) FDA Lung Cancer Approval Change For Investors?
2026-11-19 06:12 · Yahoo
Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer
2026-11-17 22:00 · Yahoo
Ziphius, a leading saRNA biotech, today announces the appointment of Mr. Antoon Loomans to its Board of Directors
2026-11-16 13:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.